A draft of an executive order detailing changes to the pharmaceutical industry has been obtained by journalists. In the document, President Trump outlines much of his earlier proposals to the industry in January. Namely, the document cites streamlined approval processes for quicker FDA regulation and turnover along with overseas drug price comparisons. The document also aims to revise many international agreements to boost international sales of US pharmaceuticals. Read the full article here.

Share This